Literature DB >> 16404496

Tuberculous peritonitis in a patient with rheumatoid arthritis treated with adalimumab.

Alfonso Gutiérrez-Macías1, Eva Lizarralde-Palacios, Pedro Martínez-Odriozola, Felipe Miguel-de la Villa.   

Abstract

We present a case of tuberculous peritonitis in a 71-year-old woman with long-standing rheumatoid arthritis treated with adalimumab, and we review the association between antitumor necrosis factor therapy and tuberculosis. Our case illustrates that the index of suspicion of tuberculosis in these patients, even with atypical clinical features, must be very high, and underscores the need of tuberculosis screening before therapy is started.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16404496     DOI: 10.1007/s10067-005-0164-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

Review 1.  New drugs for rheumatoid arthritis.

Authors:  Nancy J Olsen; C Michael Stein
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

Review 2.  Consideration of the risk and treatment of tuberculosis in patients who have rheumatoid arthritis and receive biologic treatments.

Authors:  Jeffry Bieber; Arthur Kavanaugh
Journal:  Rheum Dis Clin North Am       Date:  2004-05       Impact factor: 2.670

3.  Mycobacteria tuberculosis peritonitis associated with etanercept therapy.

Authors:  A M Manadan; J A Block; W Sequeira
Journal:  Clin Exp Rheumatol       Date:  2003 Jul-Aug       Impact factor: 4.473

Review 4.  Adalimumab: a review of side effects.

Authors:  Noah Scheinfeld
Journal:  Expert Opin Drug Saf       Date:  2005-07       Impact factor: 4.250

5.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

Review 6.  Infections associated with tumor necrosis factor-alpha antagonists.

Authors:  David J Rychly; Joseph T DiPiro
Journal:  Pharmacotherapy       Date:  2005-09       Impact factor: 4.705

7.  Increased risk of tuberculosis in patients with rheumatoid arthritis.

Authors:  Loreto Carmona; César Hernández-García; Cristina Vadillo; Esperanza Pato; Alejandro Balsa; Isidoro González-Alvaro; Miguel Angel Belmonte; Xavier Tena; Raimon Sanmartí
Journal:  J Rheumatol       Date:  2003-07       Impact factor: 4.666

8.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

9.  Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.

Authors:  Aparna K Mohan; Timothy R Coté; Joel A Block; Augustine M Manadan; Jeffrey N Siegel; M Miles Braun
Journal:  Clin Infect Dis       Date:  2004-07-16       Impact factor: 9.079

  9 in total
  2 in total

1.  Tuberculous myositis in a patient with ankylosing spondylitis treated with adalimumab.

Authors:  Valdeŕilio Feijó Azevedo; C Parchen; S A Coelho; D C Lacerda; C G Hirth
Journal:  Rheumatol Int       Date:  2009-01-14       Impact factor: 2.631

2.  Multiple organ tuberculosis of lung, pleura, and peritoneum in ankylosing spondylitis during adalimumab therapy.

Authors:  Wan-Hee Yoo
Journal:  Rheumatol Int       Date:  2010-01-05       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.